My Profile

Search abstracts

Lewis Sheiner


2018
Montreux, Switzerland



2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 25 (2016) Abstr 5865 [www.page-meeting.org/?abstract=5865]


PDF poster/presentation:
Click to open Click to open

Oral: Methodology - New Modelling Approaches


D-09 Simon Buatois Utilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients

Simon Buatois (1,2), Sylvie Retout (1), Nicolas Frey (1), Sebastian Ueckert (2,3)

(1) Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Basel, Switzerland; (2) IAME, UMR 1137, INSERM, F-75018 Paris, France, Univ Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France; (3) Pharmetheus AB, Uppsala, Sweden

Objectives: In Parkinson’s disease (PD) clinical trials, total score of clinical rating scales, such as MDS-UPDRS [1], is traditionally used to assess the treatment efficacy [2]. However, the high number of failed clinical trials has led to challenge its use as a clinical end point [3-5]. As a result, pharmaceutical companies are increasingly moving to an analysis of subsets of the scale. These subsets are often selected per items family (e.g. motor items), and do not take the sensitivity of each item to a drug effect into account, leading to a potential loss of power. The objectives of this work was first, to construct a subset of the MDS-UPDRS which maximizes the power to detect a drug effect acting on the disease progression (DEDP) in de novo PD patients,  and secondly, to compare those results with the ones obtained with an IRT-based analysis.

Methods: An updated version of the IRT model [6], integrating three different pathophysiological processes with different progression rate, was built to analyze the data from the Parkinson’s Progression Marker Initiative database [7]. Based on this model, clinical trial simulations were performed in de novo PD patients with a balanced, placebo versus disease modifying agent, parallel-arm study design. The power to detect a DEDP was computed under several scenarios (with different study durations and drug effects), through the use of three methods: a summary score based analysis i) of the total number of simulated items ii) of the optimal set of items (determined using a greedy algorithm [8]) and iii) an IRT based analysis.

Results: A three latent variables IRT based modeling allowed an adequate description of the data at both item and total score level taking into account the difficulty and the power of discrimination of each item. Compare to the classical analysis, the power to detect a DEDP was increased when using an optimal set of items (e.g. up to 20% increase for a 50% DEDP). However, it requires an accurate approximation of drug effect prior to the analysis, as the optimal set varied between scenarios. The IRT based analysis increased further the power without the need of items selection. 

Conclusions: Selection of the most sensitive items of the MDS-UPDRS score can be used to increase the power of a summary score analysis. Nevertheless, an IRT analysis based on all collected data items increase further the power to detect a DEDP without any need of an apriori assumption on its magnitude and is recommended. 



References:
[1] C G Goetz et al, Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale, Movement Disorders, 2007 Jan, 22(1):41-7
[2] Ramaker, C., Marinus, J., Stiggelbout, A. M., & Hilten, B. J. (2002). Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Movement Disorders Mov Disord., 17(5), 867-876.
[3] Kalia L, Lang A. Parkinson's disease. The Lancet. 2015;386(9996):896-912.
[4] Louis E, Tang M, Cote L, Alfaro B, Mejia H, Marder K. Progression of Parkinsonian Signs in Parkinson Disease. Arch Neurol. 1999;56(3):334.
[5] Vu T, Nutt J, Holford N. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. British Journal of Clinical Pharmacology. 2012;74(2):267-283.
[6] Buatois S, Retout S, Gieschke R, Ueckert S, Frey N. Using Item response theory to yield information from the MDS-UPDRS items in Parkinson’s disease clinical trials. http://www.page-meeting.org/?abstract=3417
[7] PPMI: Parkinson’s Progression marker initiative www.ppmi-info.org/data
[8] Cormen T. Introduction to algorithms. Cambridge, Mass.: MIT Press; 2009.